BENITEC BIOPHARMA INC
BNTCNASDAQ🏆 #3266 by market capUS Equity
$8.77▲ $0.07 (+0.80%)
Pre-market · at closeTrack BNTC
Get earnings, price moves & breaking news on Telegram
24h▲ 0.8%
7d▼ 0.5%
14d▲ 4.2%
30d▼ 10.2%
ytd▼ 35.0%
1y▼ 45.7%
🏦Market Cap
$306M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
100.0%
High
💵FCF Margin
—
⚖️P/S Ratio
4311.3x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $8.62 – $8.88
- 52-Week Range
- $8.00 – $16.76
- Volume (shares)
- 25,736
- Avg Volume (shares)
- —
- Shares Outstanding
- 34.9M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 4311.3x
- EPS (TTM)
- $-1.11
- Dividend Yield
- —
- Dilution (1yr)
- +1.3%
BENITEC BIOPHARMA INC
BNTCFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +14.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$51M▲ +22.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$17M▼ −29.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.6M▲ +1.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$179M▼ −$9M YoY
StockOtter · stockotter.spaceAbout BENITEC BIOPHARMA INC
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.